Evinacumab for Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS: The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of -49.0 percentage points (95% confidence interval [CI], -65.0 to -33.1; P<0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was -132.1 mg per deciliter (95% CI, -175.3 to -88.9; P<0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null-null variants (-43.4% vs. +16.2%) and in those with non-null variants (-49.1% vs. -3.8%). Adverse events were similar in the two groups. CONCLUSIONS: In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In total, 65 patients with HoFH were randomized to evinacumab (15 mg per kilogram body weight intravenous) or placebo every 4 weeks. Evinacumab lowered LDL-C by − 49% compared with placebo without a significant increase in adverse events. Evinacumab also significantly reduced ApoB-100 by − 37%, non-HDL by − 52%, total cholesterol by − 48%, triglycerides by − 50%, and ApoC-III by − 90%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison, evinacumab, a monoclonal antibody against ANGPTL3 that is thought to cause near-total suppression of ANGPTL3 activity, 7,14,15 reduces ApoB levels by >40% in adults with refractory hypercholesterolemia or homozygous familial hypercholesterolemia in its intravenous formulation administered at a dose of 15 mg/kg.14,15”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ELIPSE HoFH trial, evinacumab significantly reduced LDL-C levels by 49% from baseline in patients with homozygous familial hypercholesterolemia (HoFH)—a population in whom standard lipid-lowering therapies (including statins and PCSK9 inhibitors) are often ineffective due to absent or defective LDL receptors [53].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings are confirmed in the recently published ELIPSE trial (Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia), which showed a similar LDL-C lowering effect of Evinacumab in patients with hoFH with null/null and non-null/null variants.20”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationCuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationMolecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationRaal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Self-citationKöster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323
Self-citationShimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297
Cited by
Items 701–800 of 809
Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering
Gagnon, É., & Arsenault, B. J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000977
Schubert, T. J., deRichemond, C., Karalis, D. G., & Jones, L. K. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.017
Evinacumab y lomitapida en hipercolesterolemia familiar homocigótica
Portero, P. C. (2025) · Panorama actual del medicamento · doi:10.63105/pam3
Zaveri, F., & Naser, S. (2025) · Texila international journal of academic research · doi:10.21522/tijar.2014.12.02.art018
Research Progress of Remnant Cholesterol in Atherosclerotic Cardiovascular Disease
王, 怡. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551354
Kataoka, Y., Murai, K., Nicholls, S. J., Tomishima, Y., Iwai, T., Sawada, K., Matama, H., Honda, S., Takagi, K., Fujino, M., et al. (2025) · CJC Open · doi:10.1016/j.cjco.2025.06.006
Immunotherapy for the Treatment of Atherosclerotic Disease: Integrative Review
Rodrigues, L. D. S., & Bertanha, M. (2025) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2025.0005
Pharmacotherapy of Energy Metabolism in Obesity
(2025) · Frontiers Media SA eBooks · doi:10.3389/978-2-8325-6300-7
Filler, G., & Norozi, K. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1559147
Choudhary, A., Parhi, K. K., Kumar, P. V. N., Hait, A., & GOBIND, A. P. (2025) · Romanian Journal of Pharmaceutical Practice · doi:10.37897/rjphp.2025.1-2.5
Yu, J., Chengjia, L. I., Liu, Z., Chen, Y.-D. I., Yao, L., Li, D., Ma, W., Wang, Y., Yang, Y., Wang, R., et al. (2025) · medRxiv · doi:10.1101/2025.09.03.25333717
Zhang, S., Zhao, J., Xie, X., Li, L., Chen, J., Liu, H., & Wang, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00732
He, K., Ku, X., Chen, Z., Wu, C., Liao, C., Li, L., Qu, H., Hong, P., Bai, S., Cui, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.24.678175
Homozygous familial hypercholesterolemia: New therapeutic approach and a call for action!
Gallo, A., Boccara, F., & Béliard, S. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2025.09.001
Trinh, Y. W. I., Panteloglou, G., Voloviceva, E., Lone, M. A., Bernhard, S., Schlumpf, E., Frey, K., Rohrer, L., Gonzales, M. J. M., Lutz, T. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.30.679508
Evinacumab: a therapeutic agent for homozygous familial hypercholesterolemia
Blaha, V. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.073
Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials
Hooper, A. J., Parameswaran, T., & Burnett, J. R. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2571213
“After 24 weeks treatment alongside maximally tolerated lipid-lowering therapy, evinacumab reduced LDL-cholesterol levels by ~47% and TG by ~55%, irrespective of lipoprotein apheresis status [4,5].”
Zhong, C. X., Zhu, L., Liu, Y., Xu, B., & Kang, L. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39753
“Two serious adverse events of urosepsis and a suicide attempt were reported in the evinacumab group, with the patients all recovering [32].”
Александровна, С. О. (2025) · Кардиология в Беларуси · doi:10.34883/pi.2025.17.5.008
The Role of Precision Medicine in Family Health: Tailoring Treatments for Hereditary Diseases
Ajayi, R. O., Adeyemi-Benson, O. S., Adeyemi-Benson, O. A., Ogunjobi, T. T., Ukpoju-Ebonyi, O. M., & Ebonyi, J.-M. A. (2025) · Medinformatics · doi:10.47852/bonviewmedin52025796
“Combining pharmaceutical therapy with dietary adjustments, regular exercise, and smoking cessation promotes cardiovascular risk reduction [24].”
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Von Kräutern zu Pillen, Biologics und Nukleinsäuren
Lüscher, T. F., von Eckardstein, A., Beer, J. H., Räber, L., Sudano, I., Nanchen, D., Mueller, C. E., Mach, F., & Landmesser, U. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2022.02258
Life Course Approach to Familial Hypercholesterolemia
Miname, M. H., Castanhel, F. D., Mizuta, M. H., & Santos, R. D. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02328-2
“It is especially effective in LDLR null-null patients, achieving a 43% reduction in LDL-C [ 58].”
Hypolipidemic and antihyperlipidemic drugs
Vardanyan, R., & Vardanyan, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33869-4.00014-4
Therapeutic Plasma Exchange and Evinacumab for Homozygous Familial Hypercholesterolemia
Raygani, S., Sykes, A. V., Sanchez, A. P., Witztum, J. L., & Wilkinson, M. J. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.106407 · Cited by 1
Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia?
Santos, R. D. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00330-4
Guan, B., Wang, A., & Xu, H. (2023) · Figshare · doi:10.6084/m9.figshare.23930435
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Michaeli, D. T. (2024) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00035637
Guan, B., Wang, A., & Xu, H. (2023) · Figshare · doi:10.6084/m9.figshare.23930429
Wong Chong, E., Joncas, F.-H., Douville, P., Bachvarov, D. R., Diorio, C., Calon, F., Bergeron, A.-C., Blais, J., Leung, S. O., Seidah, N. G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25302989
Saghafi, S., Chamani, E., Salmani, F., Fadaei, R., Shafiei, E., Moradi, N., & Tavakoli, T. (2023) · Figshare · doi:10.6084/m9.figshare.24104428
Lauzière, A. (2023) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/27194
PREMATURE CORONARY ARTERY DISEASE DUE TO FAMILIAL HYPERCHOLESTROLEMIA IN A 26 YEAR FEMALE
Kumar, B. (2025) · International Journal of Advanced Research · doi:10.21474/ijar01/22162
Tanaka, H., Matsuura, Y., Yamamoto, K., Komaki, S., Yamaguchi, M., Moribayashi, K., Ideguchi, T., Nakai, M., Tsuruda, T., & Kaikita, K. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0264 · Cited by 1
Schonck, W. A. M., Crosti, C., Marchesin, A., Gallo, A., Kayıkçıoğlu, M., Banach, M., Cuchel, M., Jones, R. E., Kainth, P., Catapano, A. L., et al. (2025) · European Atherosclerosis Journal · doi:10.56095/eaj.v4i3.115
“Clinical studies have demonstrated that Evinacumab can reduce LDL-C levels by approximately 50% in patients with HoFH, representing a substantial improvement compared to conventional LLTs [4-6].”
Nagao, T., Arai, R., Nishiwaki, T., Tanaka, Y., Hori, K., Ebuchi, Y., & Okumura, Y. (2026) · Internal Medicine · doi:10.2169/internalmedicine.6453-25
“In addition, for patients with homozygous FH, lomitapide, a microsomal triglyceride transfer protein inhibitor, and evinacu-mab, an angiopoietin-like 3 inhibitor, have been approved and are positioned as therapeutic options for extremely severe cases (17, 18).”
The ANGPTL3-integrin α5 axis drives retinal vascular leakage in diabetic retinopathy
Ke, J., Xu, Y., Zhu, Y., Feng, X., Cao, H., Yang, L., & Zhao, D. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07710-4
“Evinacumab is a fully human monoclonal antibody targeting ANGPTL3 and has been approved for the treatment of homozygous familial hypercholesterolemia, showing superior lipid-lowering and vasoprotective effects in several studies [26–28].”
Zahrieh, D., Wang, Y., Le‐Rademacher, J. G., & Koutsoukos, T. (2026) · The New England Journal of Statistics in Data Science · doi:10.51387/26-nejsds96
Iskra, R., & Liubas, N. (2025) · Biointerface Research in Applied Chemistry · doi:10.33263/briac156.083
Dastjerdi, P., Aghababaei, M., Nikfar, R., Aghakouchakzadeh, M., Badalabadi, R. M., & Hosseini, K. (2026) · Clinical Case Reports · doi:10.1002/ccr3.72028
Silva, J. M. V., Nogueira, A. C. C., & Leite, C. B. (2026) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v12i2.24203
Representation is Prevention: Closing the Sex Gap in Novel Cardiovascular Clinical Trials
Shah, N. P., & Gulati, M. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101420
Dyslipidemia and therapies after heart transplantation: Current evidence and future directions
YADALAM, A. K., Gold, M. E., Patel, K., Razavi, A. C., Flowers, A., Seo, G., Britt, W. M., Eisenberg, S. D., Book, W. M., Rollins, J. B., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.02.021
Zhang, X., Han, Y., Zheng, L., He, X., Pu, Y., Wei, L., Wang, Y., & Xian, X. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02916-3
“Evinacumab effectively decreases LDL levels even in subjects with familial hypercholesterolemia (FH) carrying LDLR gene defects [8].”
Harangi, M., Nádró, B., Diószegi, Á., & Paragh, G. (2026) · Magyar Belorvosi Archívum · doi:10.59063/mba.2026.79.1.2
ANGPTL3 Gene Editing: Promise and Prudence
Lorenzatti, A. J. (2026) · European Cardiology Review · doi:10.15420/ecr.2026.02
ANGPTL3-lowering strategies to address residual cardiovascular risk
Mohamed, F., & Raal, F. J. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01273-z
Self-citationVolpi, L., Spira, D., Mai, K., Demuth, I., Steinhagen‐Thiessen, E., Kassner, U., & Bobbert, T. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.004 · Cited by 2
“14,22,23 To summarize, evinacumab offers a substantial LDL-C reduction, filling a therapeutic gap for HoFH patients, who do not adequately respond to conventional therapies.”
InfluentialBenabdellah, M., Mesfioui, M. B., Ouartassi, H. E., Boussaadani, B. E., & Raissuni, Z. (2026) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytag227
“11 Additionally, two young HoFH patients in whom profound plaque reduction was observed with CCTA imaging after highly intensive lipid-lowering therapy with statins, ezetimibe, LDL apheresis, and evinacumab.”
ANGPTL3 gene editing with CRISPR-Cas9: early trial insights
Tang, X. L., Hooper, A. J., & Burnett (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2656431
“The ELIPSE HoFH trial (NCT03399786), a randomized, placebo-controlled, double-blind phase III study, enrolled 65 participants with homozygous familial hypercholesterolemia (HoFH) on a background of stable lipid-lowering therapy [5].”
Nuevos fármacos hipolipemiantes en el horizonte. Un abanico de posibilidades
Sánchez-Hernández, R. M., & López, M. A. B. (2026) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2026.501807
Sahoo, S. K., Singh, P. K., Barik, R., Prakash, S., Sahoo, D., Mohanty, C. R., Malla, S. R., & Mohapatra, R. K. (2026) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytag264
“19 However, the cost and availability of these therapeutics limit their use in many health systems.”
New lipid-lowering drugs on the horizon. A range of possibilities
Sánchez-Hernández, R. M., & López, M. A. B. (2026) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2026.501807
Dababneh, M. F., Alhasso, B., Shareef, A., Kyada, A., Malathi, H., Maharana, L., Puri, D., Gupta, H., Yarmukhamedova, N. A., Sameer, H. N., et al. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10651-6
Familiäre Hypercholesterinämie – wann daran denken – wie vorgehen?
Vogt, A. (2026) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-026-00304-x
Blaszkiewicz, J., Jiang, Y.-L., Liu, J.-T., Martinez-Morant, C., Dearth, T., van Altena, C., Lamprecht, M. P., Kappler, C. S., Lee, M., Bethard, J. R., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101796
“3,22 However, it is an expensive therapy used with plasma apheresis, increasing patient burden and limiting its accessibility.”
Chinese expert consensus on the choice of initial cholesterol-lowering strategy
Wu, N., Wang, X., Ye, P., Chen, H., Chen, Z., Zhao, D., Dq, P., Guo, Y., Gao, Y., Yang, J.-G., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1798787
“A Phase III trial showed that evinacumab treatment in HoFH patients significantly reduced LDL-C by 47.1% compared to placebo for 24 weeks, with a comparable incidence of adverse events between groups (Raal et al., 2020).”
InfluentialTreatment Target Discovery From Vasculo-Protective Phenotypes
Lee, S. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.2.240
“9 In summary, genes associated with vasculo-protective phenotypes (e.g., low lipid levels and low cardiovascular risk) frequently represent suitable candidates for drug development aimed at cardiovascular disease prevention. https://doi.org/10.”
Takov, K., Depuydt, M. A. C., Stevens, C. A. T., Fogacci, F., Vico, T. A., Dalt, L. D., Mußbacher, M., Oleksiak, A., Hendrikx, T., Cutruzzolà, A., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120787
Badimón, L., Vilahur, G., & Mendieta, G. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120777
Kounatidis, D. C., Vallianou, N. G., Panagopoulos, F., Bampiolakis, A., Stamatopoulos, V., Dalamaga, Μ., Mourouzis, I. S., & Pantos, C. I. (2026) · Biomolecules · doi:10.3390/biom16060831
“In patients with refractory homozygous familial hypercholesterolemia (HoFH), ev-inacumab lowers LDL cholesterol levels by approximately 50% and TG levels by 27% [37,38].”
Karungi, I., Holven, K. B., Ray, K. K., & Elshorbagy, A. K. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01431-1
“Treatment options for HoFH have been expanded by evinacumab, which lowers LDL-C by 47% independent of the LDLR pathway [39, 40].”
Bonanni, L., Cutolo, A., & Ferri, N. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07898-z · Cited by 1
НОВІТНЯ ЛІПІДОЗНИЖУЮЧА ТЕРАПІЯ: ЗА МЕЖАМИ СТАТИНІВ
Руснак-Каушанська, О. В., Колодніцька, Н., Курелюк, А., & Велієва, Н. (2026) · ГРААЛЬ НАУКИ · doi:10.36074/grail-of-science.29.05.2026.158
Lee, M.-R. (2026) · Korean Journal of Clinical Laboratory Science · doi:10.15324/kjcls.2026.58.2.139
Complex LDLR mutations in Taiwanese familial hypercholesterolemia
Su, T., Chien, K., Lin, P., Lee, Y.-T., & Liau, C. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.67
Rossi, I., Chen, R., Hazizaj, E., Lupo, M. G., Marodin, G., Cos, S., Giannella, A., Ceolotto, G., & Ferri, N. (2026) · Cells · doi:10.3390/cells15131195
Prado, R. M., Solís, Y. G. R., Dávila, D. E. G., Fernández, L. M., Reyes, O. S. A., Ordóñez, I., Ramos, L., & González, M. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1841116
“However, the efficacy of PCSK9 inhibitors depends on residual LDL receptor activity and may be substantially reduced in patients carrying null LDLR variants (Cuchel et al., 2023; Raal et al., 2020).”
Targeting cytokine-like protein FAM3D alleviates atherosclerosis
Zhu, S., Zhu, M., Fan, F., Zm, C., Shen, Y., Li, Z., Ding, Q., Wang, X., Dong, Z. Z., Huang, Z., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102908
“39 42 Agents like ole-zarsen, 40 an antisense oligonucleotide that inhibits ApoCIII production, and evinacumab, 41,42 an mAb that neutralizes ANGPTL3, are currently undergoing clinical evaluation for their potential to reduce MACEs.”
Self-citationCurrent diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Kronenberg, F., Höllerl, F., Brath, H., Rega‐Kaun, G., Greber‐Platzer, S., Weiser, C., Klein, D. P., Riesenhuber, N., Binder, C. J., Brix, J. M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02760-6
Björnson, E., & Adiels, M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01442-y
“ANGPTL3 regulates lipoprotein lipase and endothelial lipase, and its inhibition can lower TRLs and LDLs. Evinacumab, a monoclonal antibody targeting ANGPTL3, lowers LDL-C and triglycerides and is approved for homozygous familial hypercholesterolemia [64, 65].”
Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives
Miszczak, M., Piwowarczyk, P., Sobieszek, G., Dobrowolski, P., & Prejbisz, A. (2026) · Biomedicines · doi:10.3390/biomedicines14081743
“Lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor [45], and evinacumab, a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3) [46], have also been reported to reduce Lp(a) concentrations, particularly in patients with homozygous familial hypercholesterolemia.”
Lipoprotein apheresis: still needed in many patients, or soon a historical practice?
Schettler, V. J. J., Akgun, Y., Floege, J., & Zoccali, C. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag240
“Bempedoic acid provides a statin-independent oral alternative for statin-intolerant patients, and evinacumab, targeting angiopoietin-like 3 (ANGPTL3), is effective even in HoFH because its mechanism does not depend on LDL receptor activity [ 18 ].”
Bajaj, A., McGuire, M., Shugg, S., Godin, R., & Underberg, J. A. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101790
“…in the evinacumab arm ( n = 44) than in the placebo-evinacumab arm ( n = 20) during the OLE period included influenza-like illness (4.5% vs 0), back pain (6.8% vs 0), nausea (6.8% vs 0), headache (11.4% vs 5.0%), and nasopharyngitis (11.4% vs 5.0%); there were no concerns over liver safety [24,25].”
InfluentialDamianaki, A., Stambolliu, E., Iliakis, P., Theofilis, P., Vakka, A., Kalliakouda, E., Patsalis, P., Konstantinidis, D., & Petras, D. I. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07934-y
Precision medicine breakthrough: Multi-omics integration elevates CAD risk prediction
Su, Q., Li, Q.-Y., Hu, C.-K., Huang, Y., Mo, L., HUANG, W.-Z., & Pan, D.-G. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103306
Reijman, M. D., Nigmann, C., Kusters, D. M., Planken, R. N., Loewe, C., Verpalen, V. A., Hovingh, G. K., Neyer, M., Draxler-Dworzak, S., Mair, K. S., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048419
“16,17 Subsequent studies in adults and adolescents with HoFH followed patients for up to 4 years after a 24-week course of evinacumab and found that long-term efficacy and safety of evinacumab were sustained irrespective of LDLR genotype, and background LLT, 18,19 a finding recently substantiated…”
Self-citationForrest, A. S., Majety, P., Mayer, S., & Ganda, O. P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71180
Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?
Flagiello, V., Barreby, E., Gentilucci, U. V., & Romeo, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70142
“Monoclonal antibody-mediated ANGPTL3 inhibition with evinacumab has demonstrated substantial LDL-C reduction even in individuals with homozygous LDLR deficiency, indicating lipid lowering largely independent of LDLR activity, without evidence of hepatic lipid accumulation in clinical studies [70].”
Srivastava, R. A. K. (2026) · Cells · doi:10.3390/cells15171575
“Each paradigm addresses a different biological leverage point, carries distinct safety and regulatory implications, and may be best suited to different patient populations and risk tolerances [123,159,168,219].”
InfluentialWhen Cholesterol Can Kill at 20
Chan, K., Choi, L. C.-W., & Kam, K. K. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.109787
Self-citationSabouret, P. F., Mafrica, D., Giamundo, D. M., Popiołek-Kalisz, J., Asher, E., Atar, D., & Andò, G. (2026) · Life · doi:10.3390/life16091470
“In ELIPSE HoFH, it produced an approximately 49-percentage-point placebo-corrected reduction in LDL-C despite intensive background therapy [22].”
Gaudet, D., Godin, R., Rosenson, R. S., & Watts, G. F. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.024 · Cited by 1
Self-citationZhong, W., Zhang, J., Zhu, D., Pei, H., Wu, W., Huang, R., Yin, D., Gao, X., Li, B., Lv, C. Z., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.07.017 · Cited by 1
Autosomal Recessive Hypercholesterolemia Due to a Novel Homozygous LDLRAP1 Frameshift Mutation
Gitte, P. T., Kharche, M. N., & Khedkar, U. B. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.110329
Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis
Masson, W. M., Lobo, M., MANSUR, M., Solís, C., & Nogueira, J. P. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03783-1
Remnant clearance capacity: a new framework for early type 2 diabetes pathogenesis
Nakajima, K., Murakami, M., & Tanaka, A. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121345 · Cited by 1
CRISPR therapy for dyslipidemia
Nicholls, S. J. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001062 · Cited by 1
Yang, G., Zhang, D. Y., Fischman, C. J., Cuchel, M., Suszták, K., & Rader, D. J. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.06.015
Peng, Y., Li, R., Li, H., Zhou, J., Liu, X., Valente, G., Melo, T. D. C., Chen, S., & 顾镭 (2026) · Medicine Bulletin · doi:10.1002/mdb2.70046 · Cited by 1
Hu, S., Guo, Z., Li, C., Nie, X., Wang, J., He, J., Zhuang, C., Zhang, L., Li, D., Lin, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0011
Where we have come from and where we are going in lipid therapeutics
Goldberg, A. C., & Duell, P. B. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.001
Features of Lipid Disorders in Cardiovascular–Kidney–Metabolic Syndrome
Ceasovschih, A., Şener, Y. Z., Arici, M., Cherska, M., Bianconi, V., Ejubović, M., Kotlyarov, S. N., Ristovski, V., Yetkin, A., Golforoush, P. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188317 · Cited by 1
“…and, the ANGPTL3 inhibitor evinacumab, which is approved for homozygous familial hypercholesterolaemia rather than pancreatitis prevention [117]; (v) investigational Lp(a)-lowering therapies, for which reductions in Lp(a) have been demonstrated but cardiovascular outcome data remain…”
Abril, D., López, G., Gelvez, N. Y., Navarro, L. F. G., Maldonado, L., Bernal, L. M., & Tamayo, M. L. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.022
Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers
Li, L., Feng, Y., Li, X., Yu, Z., Sun, C., Hu, L., Zhou, K., Liu, X., Yuan, Y., Li, L., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1857230
“Evinacumab, a monoclonal antibody targeting ANGPTL3, reduces atherogenic lipoproteins through a pathway that is relatively independent of the LDL receptor and has shown substantial lipid-lowering effects in patients with HoFH (116).”
Clinical management of homozygous familial hypercholesterolemia: Perspectives from an expert panel
Ruiz, Á., Campo-Torrenegra, R., Monsalve-Arango, C., Mauricio Coll, B., Gil-Forero, J., Gómez‐Mesa, J. E., Pachajoa, H., Rivera, C., Román-Gonzaléz, A., Tamayo, M. L., et al. (2026) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.13.3.988
“Patients treated with evinacumab 15 mg/ kg intravenously every four weeks achieved a 47% reduction in LDL-C at 24 weeks, irrespective of genotype (null vs. defective alleles) (145).”
InfluentialMuhammad, D. H., Hulwa, F. H., Fitria, & Putri, V. (2026) · Journal of Regenerative Medicine and Molecular Innovation
Yang, M., & Xie, X. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.08.005
Metadata
- Authors
- Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., Khilla, N., Pordy, R., Weinreich, D. M., Yancopoulos, G. D., Zhang, Y., & Gaudet, D.
- Affiliations
- University of the Witwatersrand (ZA)
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-08-20
- Volume
- 383
- Issue
- 8
- Pages
- 711-720
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3061843793
- Semantic Scholar
- 9f8bdc77b195a0ec05f5cb5d0662d5a8c5e0b865
- Cited by
- 793
- References
- 24
- Citations by year
- 2026: 126 · 2025: 129 · 2024: 139 · 2023: 123 · 2022: 130 · 2021: 123 · 2020: 22
- FWCI
- 91.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evinacumab, homozygous familial hypercholesterolemia, ANGPTL3, LDL cholesterol lowering, monoclonal antibodies, lipid-lowering therapy, atherosclerotic cardiovascular disease prevention
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adolescent, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Child, Double-Blind Method, Female, Homozygote, Humans, Hyperlipoproteinemia Type II, Infusions, Intravenous, Cholesterol, LDL, Male, Middle Aged, Mutation, Receptors, LDL, Least-Squares Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.